Clinical Trial Update: A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluated neratinib (HKI-272) in combination with paclitaxel in subjects with advanced breast cancer and other solid tumors; the trial complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nerlynx (neratinib)
• Paclitaxel (Taxol) (paclitaxel)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Advanced Breast Cancer, Advanced Malignant Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-05-09